Table 1. Clinicopathological characteristics and inflammation-based prognostic scores of patients with esophageal squamous cell carcinoma.
| Characteristic | Primary Cohort (n = 633) | Validation Cohort (n = 283) | ||
|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | |
| Sex | ||||
| Male | 484 | 76.5 | 211 | 74.6 |
| Female | 149 | 23.5 | 72 | 25.4 |
| Age | ||||
| ≤60 | 317 | 50.1 | 138 | 48.8 |
| >60 | 316 | 40.9 | 145 | 51.2 |
| BMI | ||||
| <18.5 | 76 | 12.0 | 31 | 11.0 |
| 18.5–24.5 | 492 | 77.7 | 211 | 74.6 |
| >24.5 | 65 | 10.3 | 41 | 14.4 |
| Tumor location | ||||
| Upper | 33 | 5.2 | 24 | 8.5 |
| Middle | 428 | 67.6 | 171 | 60.4 |
| Lower | 172 | 27.2 | 88 | 31.1 |
| Histological grade | ||||
| Well differentiated | 31 | 4.9 | 14 | 4.9 |
| Moderately differentiated | 325 | 51.3 | 126 | 44.5 |
| Poorly or not differentiated | 277 | 43.8 | 143 | 50.5 |
| Tumor length (cm) | ||||
| <4 | 279 | 44.1 | 114 | 40.3 |
| 4–8 | 259 | 40.9 | 113 | 39.9 |
| >8 | 95 | 15.0 | 56 | 19.8 |
| T stage | ||||
| T1a | 34 | 5.4 | 21 | 7.4 |
| T1b | 103 | 16.3 | 50 | 17.7 |
| T2 | 166 | 26.2 | 59 | 20.8 |
| T3 | 313 | 49.4 | 151 | 53.4 |
| T4a | 17 | 2.7 | 2 | 0.7 |
| Examined lymph nodes | ||||
| ≤5 | 163 | 25.7 | 36 | 12.7 |
| 6–15 | 343 | 54.2 | 171 | 60.4 |
| >15 | 127 | 20.1 | 76 | 26.9 |
| Modified N stage | ||||
| N0 (examined lymph nodes >5) | 196 | 31.0 | 123 | 43.5 |
| N0 (examined lymph nodes ≤5) | 123 | 19.4 | 30 | 10.6 |
| N1 (Positive lymph nodes 1–2) | 187 | 29.5 | 83 | 29.3 |
| N2 (Positive lymph nodes 3–6) | 97 | 15.3 | 35 | 12.4 |
| N3 (Positive lymph nodes ≥7) | 30 | 4.7 | 12 | 4.2 |
| TNM stage (AJCC, 6th) | ||||
| I | 106 | 16.7 | 59 | 20.8 |
| IIa | 203 | 32.1 | 90 | 31.8 |
| IIb | 92 | 14.5 | 41 | 14.5 |
| III | 232 | 36.7 | 93 | 32.9 |
| TNM stage (AJCC, 7th) | ||||
| Ia | 28 | 4.4 | 12 | 4.2 |
| Ib | 81 | 12.8 | 47 | 16.6 |
| IIa | 54 | 8.5 | 27 | 9.5 |
| IIb | 216 | 34.1 | 98 | 34.6 |
| IIIa | 138 | 21.8 | 58 | 20.5 |
| IIIb | 72 | 11.4 | 28 | 9.9 |
| IIIc | 44 | 7.0 | 13 | 4.6 |
| PLR | ||||
| ≤120 | 338 | 53.4 | 120 | 42.4 |
| >120 | 295 | 46.6 | 163 | 57.6 |
| NLR | ||||
| ≤1.7 | 192 | 30.3 | 98 | 34.6 |
| >1.7 | 441 | 69.7 | 185 | 65.4 |
| LMR | ||||
| ≤3.57 | 283 | 44.7 | 137 | 48.4 |
| >3.57 | 350 | 55.3 | 146 | 51.6 |
| CRP/Alb | ||||
| ≤0.06 | 206 | 32.5 | 170 | 60.1 |
| >0.06 and ≤0.12 | 287 | 45.3 | 90 | 31.8 |
| >0.12 | 140 | 22.1 | 23 | 8.1 |
| GPS | ||||
| 0 | 547 | 86.4 | 263 | 92.9 |
| 1 | 76 | 12.0 | 18 | 6.4 |
| 2 | 10 | 1.6 | 2 | 0.7 |
| mGPS | ||||
| 0 | 597 | 94.3 | 274 | 96.8 |
| 1 | 26 | 4.1 | 72 | 2.5 |
| 2 | 10 | 1.6 | 2 | 0.7 |
BMI: body mass index; PLR: platelet lymphocyte ratio; NLR: neutrophil lymphocyte ratio; LMR: lymphocyte monocyte ratio; CRP/Alb - C-reactive protein/albumin; GPS: glasgow prognostic score, mGPS – modified GPS; AJCC: American Joint Committee on Cancer